[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,780,186
  • Shares Outstanding, K 78,492
  • Annual Sales, $ 1,550 K
  • Annual Income, $ -258,760 K
  • EBIT $ -309 M
  • EBITDA $ -312 M
  • 60-Month Beta 0.90
  • Price/Sales 1,795.92
  • Price/Cash Flow N/A
  • Price/Book 6.08

Options Overview Details

View History
  • Implied Volatility 63.41% (+8.41%)
  • Historical Volatility 42.58%
  • IV Percentile 24%
  • IV Rank 20.61%
  • IV High 155.78% on 11/10/25
  • IV Low 39.43% on 05/12/26
  • Expected Move (DTE 31) 0.00 (0.00%)
  • Put/Call Vol Ratio 1.04
  • Today's Volume 2,067
  • Volume Avg (30-Day) 294
  • Put/Call OI Ratio 1.44
  • Today's Open Interest 7,677
  • Open Int (30-Day) 8,158
  • Expected Range 35.66 to 35.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.04
  • Number of Estimates 3
  • High Estimate $-1.02
  • Low Estimate $-1.06
  • Prior Year $-0.85
  • Growth Rate Est. (year over year) -22.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.26 +10.54%
on 06/22/26
40.30 -11.51%
on 07/07/26
+3.23 (+9.96%)
since 06/18/26
3-Month
28.38 +25.65%
on 06/08/26
40.30 -11.51%
on 07/07/26
+1.41 (+4.12%)
since 04/21/26
52-Week
19.72 +80.81%
on 08/11/25
40.30 -11.51%
on 07/07/26
+13.60 (+61.65%)
since 07/21/25

Most Recent Stories

More News
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Study did not meet key efficacy objectives Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimen Profound systemic mast cell depletion,...

CLDX : 35.66 (+0.68%)
MoneyMasters Podcast: Where to Invest NOW in AI, Biotech, Small Caps, & Gold!

In this timely and actionable episode, Jeffrey Hirsch, John McCamant, and Luke Lloyd discuss the best profit opportunities for the second half of 2026.

GWRE : 142.53 (-4.46%)
CLDX : 35.66 (+0.68%)
PGEN : 5.49 (+8.28%)
NVO : 49.38 (-0.46%)
AKAM : 124.91 (+1.45%)
SNEX : 74.55 (+5.43%)
ORCL : 127.05 (+4.67%)
ABBV : 256.10 (+1.07%)
GDXJ : 97.09 (+5.92%)
RSP : 212.76 (+0.16%)
VKTX : 37.95 (+4.32%)
LLY : 1,175.41 (+2.49%)
Celldex Announces Planned Transition of Chief Financial Officer

HAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to retire...

CLDX : 35.66 (+0.68%)
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSU Seven months after the completion of dosing (Week 76), up...

CLDX : 35.66 (+0.68%)
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseases CDX-622 targets the soluble form of stem cell...

CLDX : 35.66 (+0.68%)
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress 

-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria -- -- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX)...

CLDX : 35.66 (+0.68%)
Celldex: Q1 Earnings Snapshot

Celldex: Q1 Earnings Snapshot

CLDX : 35.66 (+0.68%)
Celldex Reports First Quarter Financial Results and Provides Corporate Update

Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for 2027...

CLDX : 35.66 (+0.68%)
Celldex to Present at Upcoming Investor Conference

HAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at H.C. Wainwright’s 4th Annual Inflammatory Skin Disease...

CLDX : 35.66 (+0.68%)
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

HAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public...

CLDX : 35.66 (+0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

3rd Resistance Point 37.69
2nd Resistance Point 36.84
1st Resistance Point 36.25
Last Price 35.66
1st Support Level 34.82
2nd Support Level 33.97
3rd Support Level 33.38

See More

52-Week High 40.30
Last Price 35.66
Fibonacci 61.8% 32.44
Fibonacci 50% 30.01
Fibonacci 38.2% 27.58
52-Week Low 19.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.